HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.

Abstract
Clofarabine has shown activity and tolerability in older patients with acute myeloid leukemia (AML). We investigated the safety and tolerability of an oral formulation of clofarabine for consolidation therapy of patients aged 60 and older with AML. In this phase I study, twenty-two patients older than 60 years with AML in first complete remission were treated once daily with oral clofarabine for 14 or 21 days of a 28-day cycle, for up to five cycles. Dose escalation from 1 mg to 6 mg daily using a 3 + 3 design was used to determine dose-limiting toxicities (DLT), the maximum tolerated dose (MTD), and tolerability of oral clofarabine. No DLTs or Grade 3-4 nonhematologic toxicities were observed. The primary toxicities were hematologic, including uncomplicated grade 3-4 neutropenia (50%) and thrombocytopenia (50%). Given that myelosuppression necessitating dose delays/reductions was observed more commonly at higher doses, the recommended phase II dose is 2 mg daily for 21 of 28 days. At doses equal to or greater than 2 mg, the median relapse-free survival was 28.35 months. Oral clofarabine was well-tolerated with encouraging activity in patients older than 60 years. Further investigation of oral clofarabine as a consolidation and/or maintenance therapy in AML for older individuals is warranted. (ClinicalTrials.gov:NCT00727766).
AuthorsMeagan A Jacoby, Michael G Martin, Geoffrey L Uy, Peter Westervelt, John F Dipersio, Amanda Cashen, Keith Stockerl-Goldstein, Ravi Vij, Jingqin Luo, Teresa Reineck, Noel Bernabe, Camille N Abboud
JournalAmerican journal of hematology (Am J Hematol) Vol. 89 Issue 5 Pg. 487-92 (May 2014) ISSN: 1096-8652 [Electronic] United States
PMID24415560 (Publication Type: Clinical Trial, Phase I, Journal Article)
CopyrightCopyright © 2014 Wiley Periodicals, Inc.
Chemical References
  • Adenine Nucleotides
  • Antimetabolites, Antineoplastic
  • Arabinonucleosides
  • Clofarabine
Topics
  • Adenine Nucleotides (administration & dosage, adverse effects)
  • Administration, Oral
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage, adverse effects)
  • Arabinonucleosides (administration & dosage, adverse effects)
  • Clofarabine
  • Cohort Studies
  • Consolidation Chemotherapy
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Leukemia, Myeloid, Acute (drug therapy, pathology)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: